Jefferies Financial Group Inc. Takes $994,000 Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

Jefferies Financial Group Inc. bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,725 shares of the company’s stock, valued at approximately $994,000.

Other institutional investors have also modified their holdings of the company. IFP Advisors Inc acquired a new stake in shares of Revolution Medicines in the fourth quarter valued at about $34,000. Sterling Capital Management LLC lifted its stake in shares of Revolution Medicines by 588.7% in the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after buying an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Revolution Medicines by 368.3% in the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company’s stock worth $90,000 after buying an additional 1,613 shares in the last quarter. Kapitalo Investimentos Ltda purchased a new position in shares of Revolution Medicines in the fourth quarter worth about $104,000. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Revolution Medicines by 521.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company’s stock worth $165,000 after buying an additional 3,178 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Trading Down 0.1%

Revolution Medicines stock opened at $39.44 on Friday. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $62.40. The stock has a market cap of $7.35 billion, a P/E ratio of -10.99 and a beta of 1.11. The company has a 50-day moving average price of $37.48 and a 200 day moving average price of $43.25.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same quarter last year, the business posted ($0.70) EPS. As a group, analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RVMD. Oppenheimer raised their price target on shares of Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Wedbush reissued an “outperform” rating and issued a $67.00 price target on shares of Revolution Medicines in a research note on Thursday, May 8th. Guggenheim decreased their price target on shares of Revolution Medicines from $87.00 to $80.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $57.00 price target on shares of Revolution Medicines in a research note on Thursday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $72.00 price target (down from $73.00) on shares of Revolution Medicines in a research note on Wednesday. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $67.08.

Insider Buying and Selling at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the completion of the transaction, the insider now owns 441,564 shares in the company, valued at approximately $17,238,658.56. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the completion of the transaction, the chief financial officer now owns 115,006 shares of the company’s stock, valued at $4,489,834.24. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock worth $650,406 over the last three months. Insiders own 8.20% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.